News & Insights
Sort By
Insights 11 Results
Insights
|January 21, 2022
January 21 Update - U.S. Supreme Court Blocks Federal COVID Vaccine and Testing Mandate
UPDATE: On January 13, 2022, the U.S. Supreme Court found that the Federal OSHA’s COVID vaccine ETS, targeting nearly all large U.S. employers and imposing significant penalties on noncompliant employees and employers, is a “broad public health measure” outside of OSHA’s purview.
This is an update to our October 1, 2021 Preparing for a Return to the Workplace, Employers Are Making Big Decisions (UPDATED) article.
Insights
|November 16, 2021
Returning to the Workplace VC Survey Report
Gunderson Dettmer is pleased to announce its Returning to the Workplace Survey Report. This report summarizes the data gathered from over 250 VC firms.
Insights
|October 25, 2021
Returning to the Workplace Company Survey Results
Gunderson Dettmer is pleased to announce its Returning to the Workplace Survey Report. This Report summarizes the data gathered from over 230 companies in the venture-backed startup ecosystem. The results were presented at the National Venture Capital Association, Strategic Operations and Policy Summit Return to the Workplace panel on Thursday, October 21, 2021.
Client News 2 Results
Client News
|January 29, 2018
Gunderson Dettmer advises Fullscreen in acquisition by Otter Media
Gunderson Dettmer represented Fullscreen in the buyout of the company’s remaining stakeholders. In 2014, controlling interest in Fullscreen was sold to Otter Media, a joint venture created by AT&T and The Chernin Group. AT&T is now buying out The Chernin Group as well as the minority stockholders in Fullscreen and another partially owned subsidiary.
Client News
|November 14, 2017
Gunderson Dettmer represents Syapse Inc in latest financing round
Gunderson Dettmer served as lead counsel to Syapse Inc in its $30 million Series D financing from Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics and Social Capital, as well as new investors Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund and Roche Venture Fund.